159 related articles for article (PubMed ID: 36119747)
1. Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China.
Jiang Y; Xie J
Front Cardiovasc Med; 2022; 9():946399. PubMed ID: 36119747
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
Tang Y; Sang H
Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
[No Abstract] [Full Text] [Related]
3. Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Tsutsui H; Sakamaki H; Momomura SI; Sakata Y; Kotobuki Y; Linden S; Idehara K; Nitta D
ESC Heart Fail; 2024 Feb; 11(1):261-270. PubMed ID: 37969049
[TBL] [Abstract][Full Text] [Related]
4. SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study.
Lu H; Shang P; Zhou D
Front Pharmacol; 2023; 14():1155210. PubMed ID: 37771722
[No Abstract] [Full Text] [Related]
5. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
Lou Y; Hu T; Huang J
Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness Evaluation of Add-on Empagliflozin in Patients With Heart Failure and a Reduced Ejection Fraction From the Healthcare System's Perspective in the Asia-Pacific Region.
Liao CT; Yang CT; Kuo FH; Lee MC; Chang WT; Tang HJ; Hua YM; Chang HY; Chen ZC; Strong C; Ou HT; Toh HS
Front Cardiovasc Med; 2021; 8():750381. PubMed ID: 34778407
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
Jiang Y; Zheng R; Sang H
Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
[No Abstract] [Full Text] [Related]
8. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Empagliflozin in Patients With Heart Failure With Preserved Ejection Fraction.
Zheng J; Parizo JT; Spertus JA; Heidenreich PA; Sandhu AT
JAMA Intern Med; 2022 Dec; 182(12):1278-1288. PubMed ID: 36342696
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Empagliflozin in Combination with Standard Care versus Standard Care Only in the Treatment of Heart Failure Patients in Finland.
Hallinen T; Kivelä S; Soini E; Harjola VP; Pesonen M
Clinicoecon Outcomes Res; 2023; 15():1-13. PubMed ID: 36636485
[TBL] [Abstract][Full Text] [Related]
11. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
[No Abstract] [Full Text] [Related]
12. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
[TBL] [Abstract][Full Text] [Related]
13. Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
Kolovos S; Bellanca L; Groyer H; Rosano GMC; Solé A; Gaultney J; Linden S
ESC Heart Fail; 2023 Dec; 10(6):3385-3397. PubMed ID: 37670496
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
Tang Y; Sang H
ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
Ong SC; Low JZ; Linden S
Front Pharmacol; 2023; 14():1195124. PubMed ID: 37342587
[No Abstract] [Full Text] [Related]
16. Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction.
Krittayaphong R; Permsuwan U
Am J Cardiovasc Drugs; 2022 Sep; 22(5):577-590. PubMed ID: 35796952
[TBL] [Abstract][Full Text] [Related]
17. Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE
Fauchier L; Lamblin N; Tardu J; Bellier L; Groyer H; Ittah D; Chollet J; Linden S; Levy P
Pharmacoecon Open; 2024 Jan; 8(1):19-30. PubMed ID: 37606866
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
[TBL] [Abstract][Full Text] [Related]
19. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China.
Sang H; Wan Y; Ma Z; Zhang S; Zhao Q
Front Cardiovasc Med; 2022; 9():1022020. PubMed ID: 36465457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
